Opportunity

Simpler Grants.gov #PAR-25-103

NIH Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)

Buyer

National Institutes of Health

Posted

November 05, 2024

Respond By

October 25, 2027

Identifier

PAR-25-103

NAICS

541715

The National Institutes of Health (NIH) is seeking applications for the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional): - Government Buyer: - National Institutes of Health (NIH) - Purpose: - Support for planning and preparatory studies to facilitate well-designed clinical trials in cancer prevention and control - Focus areas include prevention, health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and long-term outcomes for cancer survivors - Products/Services Requested: - No specific products or OEMs requested; this is a grant for research planning and preparatory services - Main service: Clinical trials planning and preparatory studies - Unique/Notable Requirements: - Open to a broad range of applicants, including businesses, educational institutions, government agencies, nonprofits, and other organizations - Emphasis on addressing information gaps to improve trial design, feasibility, and reduce protocol changes and costs - OEMs and Vendors: - No OEMs or vendors specified, as this is a research grant opportunity - Place of Performance: - National Institutes of Health (NIH)

Description

This funding opportunity aims to support well-planned clinical trials across the cancer prevention and control spectrum. The focus is on improving prevention, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and long-term outcomes of cancer survivors. The program addresses information gaps that can lead to protocol changes and increased costs by facilitating preparatory studies to improve trial design and feasibility. This initiative seeks to save time and resources for the National Cancer Institute by enhancing trial planning and testing new trial designs.

View original listing